Compare ADM & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADM | WAT |
|---|---|---|
| Founded | 1902 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4B | 22.5B |
| IPO Year | N/A | 1995 |
| Metric | ADM | WAT |
|---|---|---|
| Price | $57.59 | $383.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 15 |
| Target Price | $55.67 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 2.7M | 586.9K |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | N/A | ★ 3.82 |
| EPS | 2.46 | ★ 10.88 |
| Revenue | ★ $83,211,000,000.00 | $3,105,638,000.00 |
| Revenue This Year | N/A | $7.96 |
| Revenue Next Year | $4.44 | $6.32 |
| P/E Ratio | ★ $23.35 | $35.23 |
| Revenue Growth | N/A | ★ 6.90 |
| 52 Week Low | $40.98 | $275.05 |
| 52 Week High | $65.00 | $423.56 |
| Indicator | ADM | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 50.58 |
| Support Level | $57.89 | $372.17 |
| Resistance Level | $60.59 | $385.69 |
| Average True Range (ATR) | 1.27 | 8.82 |
| MACD | -0.14 | -2.82 |
| Stochastic Oscillator | 11.11 | 39.34 |
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.